Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis.

Published byΛυσιστράτος Πανταζής Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis."— Presentation transcript:

1 Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis Wild-type (WT) and Toll-IL-1 receptor domain–containing adaptor inducing interferon-β (TRIF)–deficient mice treated with glatiramer acetate (GA) or vehicle (n = 5 mice/group) were injected IP with (A) lipopolysaccharide (LPS) (100 ng/kg) or (B) Pam3CSK4 (100 ng/kg). TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis Wild-type (WT) and Toll-IL-1 receptor domain–containing adaptor inducing interferon-β (TRIF)–deficient mice treated with glatiramer acetate (GA) or vehicle (n = 5 mice/group) were injected IP with (A) lipopolysaccharide (LPS) (100 ng/kg) or (B) Pam3CSK4 (100 ng/kg). (C) Myeloid differentiation primary response gene 88 (MyD88)–deficient mice were injected IP with Poly(I:C) (10 μg/kg). Serum levels of tumor necrosis factor (TNF) and interleukin (IL)–6 were quantitated by ELISA 5 hours after injection. Results are presented as the mean ± SEM (n = 3) of 2 experiments that provided similar results; *p < 0.05, **p < 0.01, ***p < as determined by Student t test. (D) On day 0, C57BL/6J WT (left) or TRIF-deficient mice (right) mice were immunized with MOG peptide (p35-55; 50 μg). GA (250 μg) was administered once (SC in incomplete Freund's adjuvant [IFA]) on the same day as immunization (day 0). Control mice received a single SC injection of IFA. For all experimental autoimmune encephalomyelitis experiments, mean disease score ±SEM is shown. *p < 0.05 as determined by Mann-Whitney U test. Results shown are representative of 3 independent experiments. Nicolas Molnarfi et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e179 © 2015 American Academy of Neurology

Download ppt "Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis."

Similar presentations

Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics
From: Effective Arrestin–Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis Trans. Vis. Sci.

From: Effective Arrestin–Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis Trans. Vis. Sci.
Figure 5 Mononuclear cell subset isolation from spinal cord of mice with experimental autoimmune encephalomeylitis Mononuclear cell subset isolation from.

Figure 5 Mononuclear cell subset isolation from spinal cord of mice with experimental autoimmune encephalomeylitis Mononuclear cell subset isolation from.
Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Volume 18, Issue 5, Pages (May 2010)

Volume 18, Issue 5, Pages (May 2010)
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell- Mediated Antiviral Innate Immunity  Rui Aoki, Tatsuyoshi Kawamura, Fumi.

The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell- Mediated Antiviral Innate Immunity  Rui Aoki, Tatsuyoshi Kawamura, Fumi.
Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.
Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.
Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.

Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.
Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.

Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.
Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.

Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.
Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.

Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.
Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Similar presentations

Ads by Google